Tacalyx GmbH has selected its first clinical candidate, TCX-201, and secured €11 million (US$12.8 million) in a first closing of its seed extension round to support the program’s progression through preclinical development. TCX-201 is an antibody-drug conjugate (ADC) against an undisclosed tumor-associated carbohydrate antigen (TACA).
Ferrosa Therapeutics AG has announced a $3.5 million seed financing to support the development of a first-in-class bispecific antibody (FRS-101) to treat anemia of inflammation across chronic kidney disease, autoimmune disease and oncology indications.
Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin).
